# of Displayed Technologies: 9 / 9

Applied Category Filter (Click To Remove): Drug Delivery


Categories

Biomimetic vitreous substitute with ocular drug delivery
TS-044490 — Methods and compositions for an antioxidant releasing hydrogel vitreous substitute
The vitreous humor is a fragile, transparent tissue between the lens and the retina of the eye that maintains the shape of the eye, acts as a shock absorber, and enables nutrient diffusion to ocular tissues. The vitreous also plays a key role in oxygen homeostasis. Over time, the vitreous degrades…
  • College: College of Engineering (COE)
  • Inventors: Swindle-Reilly, Katelyn; Reilly, Matthew; Tram, Nguyen "Archie"
  • Licensing Officer: Flammang, Ann Marie

Nanoparticle Composition for Nucleic Acid Delivery
TS-044109 — Lipid nanoparticles (LNs) usable for the delivery of therapeutic compositions, including, but not limited to nucleic acids (NAs).
Nucleic Acid (NA) based therapies are used to inhibit gene expression. Lipid nanoparticles (LNs) are capable of carrying these therapies into cells. However, this delivery requires overcoming several physiological barriers. For instance, one barrier is the acidic endosome conditions within the cel…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

A Bi-layered Capsule for Sustainable Delivery of Protein Therapeutics
TS-042858 — A biodegradable drug delivery system for the treatment of disease, especially ophthalmic diseases including age-related macular degeneration (AMD). The device will be injected and can control drug release for at least 6 months following the initial injection.
Retinal diseases can be extremely difficult to monitor once procedures have been initiated. AMD is the fourth most common causes of blindness and requires monthly injections to manage the effects of the disease and prevent permanent blindness. However, receiving recurrent injections can potentiall…
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Coutinho da Silva, Marco; Lannutti, John; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Flammang, Ann Marie

Multifunctional RNA Nanoparticles and Methods for Treating Cancer
TS-040289 — Three-way junction nanoparticles for delivery of tamoxifen and other therapeutics directly to tumor cells.
Most breast cancers express estrogen receptor alpha (ER α) and antagonists of ER α drugs, such as tamoxifen, have been widely used for their treatment. Unfortunately, up to half of all ER α -positive tumors have intrinsic or acquired endocrine therapy resistance. Recent studies b…
  • College: College of Pharmacy
  • Inventors: Zhang, Xiaoting; Guo, Peixuan
  • Licensing Officer: Flammang, Ann Marie

Novel compositions of nanoparticles for nucleic acid therapeutic delivery
TS-040254 — Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.
Lipid-based nanoparticles (LNPs) have been extensively utilized in nucleic acid delivery. However, there are a number of challenges associated with LNP formulation. It is difficult to make sub-100-nm LNPs with a high nucleic acid concentration by traditional self-assembly methods. LNP synthesis ty…
  • College: College of Pharmacy
  • Inventors: Lee, Robert
  • Licensing Officer: Flammang, Ann Marie

Sustained Release Microparticles for the Treatment of Ocular Diseases
TS-038312 — A novel, intravitreal microparticle injection capable of controlled-release of protein therapies (including anti-VEGF) for tunable periods of 6-12 months after injection for the treatment of age-related macular degeneration.
Age-related macular degeneration (AMD) is the leading cause of blindness in individuals 65 and older and is the third leading cause of blindness worldwide. Wet AMD is characterized by abnormal growth of leaky blood vessels leading to damage to the macula of the retina resulting in vision loss and …
  • College: College of Engineering (COE)
  • Inventors: Jiang, Pengfei; Ohr, Matthew; Swindle-Reilly, Katelyn
  • Licensing Officer: Flammang, Ann Marie

Antisense Morpholino Treatment to Increase SMN Levels and Treat Spinal Muscular Atrophy
TS-037648 — A treatment for spinal muscular atrophy.
Spinal Muscular Atrophy (SMA) is caused by deletion or mutation of SMN1 and retention of SMN2, this in turn leads to reduced levels of the full SMN protein. SMA is the second leading cause of neuromuscular disease, and many people living with SMA need round-the-clock care from their families and a…
  • College: College of Medicine (COM)
  • Inventors: Burghes, Arthur; Porensky, Paul
  • Licensing Officer: Flammang, Ann Marie

Self-Assembly of Therapeutic-Agent Nanostructures
TS-014812 — An improved delivery mechanism has been developed for hydrophobic drugs such as camptothecin which will increase chemotherapeutic efficacy.
Many cancer therapeutics exhibit extremely toxic side effects or have limited efficacy due to low bio-availability. Existing drug delivery technologies can add excessive mass to the therapeutic, grossly expanding the dosage necessary for response. Camptothecin (CPT) is a naturally occurring compou…
  • College: College of Arts & Sciences
  • Inventors: Parquette, Jonathan; Grinstaff, Mark; Kaplan, Jonah; Kim, Se Hye
  • Licensing Officer: Flammang, Ann Marie

Loading icon